<DOC>
	<DOCNO>NCT00548847</DOCNO>
	<brief_summary>The relapse acute leukemia , MDS blast phase CML allogeneic transplantation affect approximately 1/3 1/2 transplant recipient main cause treatment failure . There currently effective standard treatment condition . This study test activity feasibility use regimen boost immune system order treat AML , ALL , blast phase CML , MDS relapse allogeneic transplantation .</brief_summary>
	<brief_title>Immunotherapy Acute Myeloid Leukemia ( AML ) , Acute Lymphoblastic Leukemia ( ALL ) , Blast Phase Chronic Myelogenous Leukemia ( BP CML ) , Myelodysplastic Syndrome ( MDS ) Relapse After Allogeneic Transplantation</brief_title>
	<detailed_description>This pilot phase II open label study test activity feasibility utilize regimen boost immune system order treat AML , ALL , blast phase CML , MDS relapse allogeneic transplantation . The regimen step-wise use withdrawal immunosuppression , cytoreduction need , administration granulocyte-macrophage colony-stimulating factor ( GM-CSF ) pegylated interferon ( IFN ) α-2b patient relapse allogeneic transplant ass efficacy . Relapse major problem follow allogeneic hematopoietic progenitor cell transplant . There currently standard way treat leukemia relapse transplant , patient poor prognosis . A retrospective analysis patient treat Emory show administration GM-CSF interferon-alpha-2b well-tolerated affected long-term remission small number relapse patient ( allogeneic transplant ) . Pre-clinical clinical data center show relapsed leukemic blast down-regulation co-stimulatory molecule tendency evade immune system . Cytokines up-regulate co-stimulatory molecule leukemic blast show increase cytotoxicity T-cells . This effect may beneficial graft vs. leukemia effect patient relapse allogeneic transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Age &gt; 1 year . 2 . Patients receive allogeneic transplant treat AML , ALL , MDS , CML relapse progression AML , ALL , MDS , CML eligible participate study . Relapse define : reappearance leukemic blast determine morphologic analysis blood marrow , reappearance phenotypic population leukemia blast flow cytometric analysis blood marrow , reappearance chromosome abnormality associate original leukemia determine chromosomal fluorescence situ hybridization ( FISH ) testing ( ex : translocation chromosomes 9 22 CML ) , reappearance molecular marker associate original leukemia determine polymerase chain reaction ( PCR ) ( ex : breakpoint cluster region [ BCR ] Abelson murine leukemia [ ABL ] CML ALL ) . *Patients receive allogeneic transplantation treat AML , ALL , MDS , CML detectable disease , achieve remission leukemia transplant eligible . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 adult , Lansky status 60 % child . 4 . Liver function test ( aspartate transaminase [ AST ] /alanine aminotransferase [ ALT ] /bilirubin ) &lt; 5x upper limit normal . 5 . Creatinine &lt; 3x upper limit normal . 6 . Lack active grade 24 acute graftversushost disease ( GVHD ) 3 week discontinuation immunosuppression . 7 . Patients limited stage extensive stage chronic GVHD mild severity ( lichenoid change ) , require &lt; prednisone 10 mg/m² daily include . 8 . Recipients graft procure related unrelated donor level human leukocyte antigen ( HLA ) matching . 1 . Pregnant patient exclude due unknown risk unborn fetus cytokine . 2 . Allergy component interferonalpha2b GMCSF . 3 . Current uncontrolled infection . 4 . Current grade 24 acute GVHD chronic extensive GVHD moderate severe nature , require treatment 10 mg/m² prednisone daily . 5 . Uncompensated heart failure , New York Heart Association ( NYHA ) class IIIIV : Class I : patient limitation activity ; suffer symptom ordinary activity ; Class II : patient slight , mild limitation activity ; comfortable rest mild exertion ; Class III : patient marked limitation activity ; comfortable rest ; Class IV : patient complete rest , confine bed chair ; physical activity bring discomfort symptom occur rest . 6 . Breast feeding , due unknown risk infant . 7 . Inability give inform consent . 8 . Children 1 year age .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
</DOC>